![](/img/cover-not-exists.png)
Point-of-care testing shows clinically relevant variation in the degree of inhibition of platelets by standard-dose abciximab therapy during percutaneous coronary intervention
Michael J. Ray, Darren L. Walters, Nicholas Bett, James Cameron, Peter Wood, Con AroneyVolume:
62
Year:
2004
Language:
english
Pages:
5
DOI:
10.1002/ccd.20058
File:
PDF, 93 KB
english, 2004